Tin tức & Cập nhật
Lọc theo Chuyên ngành:

Alectinib trumps crizotinib for ALK+ NSCLC
13 Jan 2025
bởiAudrey Abella
In the 7-year update of the phase III ALESIA trial, alectinib outdoes crizotinib for Asian patients with treatment-naïve, advanced or metastatic ALK+ non-small-cell lung cancer (NSCLC).
Alectinib trumps crizotinib for ALK+ NSCLC
13 Jan 2025
Survival benefit with STRIDE for HCC sustained at 5 years
10 Jan 2025
bởiAudrey Abella
The updated exploratory analysis of the phase III HIMALAYA trial demonstrates a significant overall survival (OS) benefit at 5 years with the STRIDE* regimen comprising tremelimumab and durvalumab for patients with unresectable hepatocellular carcinoma (HCC).